ArticleImmunity2013
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.
Article in Immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 5 syntheses or guidelines pooled it, 301 citations in OpenAlex.
- miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.International journal of molecular sciences · 2022Pooled it
- Interpretation of T cell states from single-cell transcriptomics data using reference atlases.Nature communications · 2021Pooled it
- Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies.World journal of surgical oncology · 2014Pooled it
- Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies.PloS one · 2014Pooled it
- Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.JCI insight · 2018Trial
- MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection.Immunology · 2015Trial
- T-cell miR-155 regulates the response to tumor-specific mRNA vaccines in a murine model of acute myeloid leukemia.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Allosteric DNAzyme-Enabled Sensitive and Multiplex Detection of Biomarkers for Rapid Diagnosis of Urinary Tract Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity.Cancer immunology, immunotherapy : CII · 2026Article
- New insight into the role of SOCS family in immune regulation and autoimmune pathogenesis.Journal of advanced research · 2026Review
- Temporal transcriptional dynamics in cutaneous leishmaniasis reveal novel targets for therapeutic interventions in a dermal mouse model.Frontiers in immunology · 2026Article
- MicroRNA-targeted reprogramming of CD8+ T cells against cancer.Frontiers in immunology · 2026Review
- Intertwined roles of microRNA-155 and metformin in osteoarthritis: Novel potential diagnostic, prognostic, and therapeutic modulators.World journal of orthopedics · 2025Review
- Young extracellular vesicles restore burn-induced adipose tissue immunometabolic and mitochondrial function in older mice.Scientific reports · 2025Article
- Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8Science advances · 2025Article
- Interplay between innate-like T-cells and microRNAs in cancer immunity.Discover oncology · 2025Review
- Review
- A microRNA-regulated transcriptional state defines intratumoral CD8Cell reports · 2025Article
- Exploring the regulatory role of small RNAs in modulating host-pathogen interactions: implications for bacterial and viral infections.Molecular biology reports · 2025Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 2 countries.
Funding
Abstract
MicroRNAs (miRNAs) regulate the function of several immune cells, but their role in promoting CD8(+) T cell immunity remains unknown. Here we report that miRNA-155 is required for CD8(+) T cell responses to both virus and cancer. In the absence of miRNA-155, accumulation of effector CD8(+) T cells was severely reduced during acute and chronic viral infections and control of virus replication was impaired. Similarly, Mir155(-/-) CD8(+) T cells were ineffective at controlling tumor growth, whereas miRNA-155 overexpression enhanced the antitumor response. miRNA-155 deficiency resulted in accumulation of suppressor of cytokine signaling-1 (SOCS-1) causing defective cytokine signaling through STAT5. Consistently, enforced expression of SOCS-1 in CD8(+) T cells phenocopied the miRNA-155 deficiency, whereas SOCS-1 silencing augmented tumor destruction. These findings identify miRNA-155 and its target SOCS-1 as key regulators of effector CD8(+) T cells that can be modulated to potentiate immunotherapies for infectious diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.